The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comprehensive study of risk factors for chemotherapy-induced nausea and vomiting in cancer patients receiving cisplatin-based chemotherapy: A TRIPLE pharmacogenomics study.
 
Hideaki Ayuhara
Honoraria - Chugai Pharma; Taiho Pharmaceutical
 
Daiki Tsuji
Research Funding - Yakult Honsha (Inst)
 
Mari Yokoi
No Relationships to Disclose
 
Kenichi Suzuki
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yohei Kawasaki
No Relationships to Disclose
 
Masahiko Nakao
No Relationships to Disclose
 
Yuki Kogure
Honoraria - Bayer Yakuhin; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Lilly; Ono Pharmaceutical; Sanofi; Sawai Pharmaceutical Co
 
Kazuhiko Shibata
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Lilly Japan; Taiho Pharmaceutical
 
Toshinobu Hayashi
Honoraria - Chugai Pharma; Taiho Pharmaceutical
 
Keita Hirai
No Relationships to Disclose
 
Kazuyuki Inoue
No Relationships to Disclose
 
Toshihiro Hama
Honoraria - Chugai Pharma; Eisai; Lilly Japan; Mochida Pharmaceutical Co. Ltd.; Taiho Pharmaceutical; Takeda; TERUMO; Yakult Pharmaceutical
Consulting or Advisory Role - Meiji Seika Kaisha; TOWA
Research Funding - Sawai Pharmaceutical Co; Yakult Honsha
 
Koji Takeda
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst)
 
Makoto Nishio
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Kunihiko Itoh
No Relationships to Disclose